<DOC>
	<DOCNO>NCT01124279</DOCNO>
	<brief_summary>To determine bioavailability effect food pharmacokinetics fast fed condition</brief_summary>
	<brief_title>Single-dose , Pharmacokinetics AMG 853 Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Nonnicotine tobacco use , healthy male and/or female subject 18 55 year age , inclusive , history evidence clinically relevant medical disorder determine investigator consultation Amgen physician Females must nonreproductive potential ( ie , postmenopausal history menses 1 year FSH consistent postmenopausal status per laboratory range ; history hysterectomy ; history bilateral tubal ligation ; history bilateral oophorectomy ) . Physical examination , clinical laboratory test value ECGs clinically acceptable investigator Amgen . Males must agree use highly effective method birth control duration study continue 12 week last dose AMG 853 . Highly effective method birth control ( i.e. , failure rate le 1 % per year ) include sexual abstinence , vasectomy condom supplement use spermicide , available , combination one follow method use female partner : region spermicide available , diaphragm cervical/vault cap supplement spermicide , hormonal birth control ( implant , injectables , combine oral contraceptive ) , intrauterine device ( IUDs ) . Male subject whose partner become pregnant study receive subsequent schedule dos , must practice sexual abstinence use condom two week follow last dose , follow safety end study . The pregnant partner information report Amgen per Pregnancy Notification Worksheet . Body mass index 18 30 kg/m2 , inclusive . History evidence clinically significant disorder , condition disease , opinion investigator Amgen physician , would pose risk subject safety interfere study evaluation , procedure , completion . Creatinine clearance within screen period le 80 mL/min calculate CockcroftGault method . History suggestive esophageal , gastric , duodenal ulceration bowel disease ( include limit peptic ulceration , gastrointestinal bleeding , ulcerative colitis , Crohn 's disease , irritable bowel syndrome ) , history gastrointestinal surgery uncomplicated appendectomy . Any positive test cotinine ( tobacco use ) day dose treatment period ( day 1 , 7 , 14 21 ) . A positive cotinine level define level exceed upper limit normal per local laboratory reference range . Known substance abuse ( eg , alcohol , licit illicit drug ) within 1 year dosing . Any positive test drug alcohol use day dose treatment period ( day 1 , 7 , 14 21 ) . Alcohol consume within 48 hour day 1 throughout study . Females lactating/breastfeeding . Males pregnant partner . Subjects require specialized diet dietary restriction would prevent comply study requirement . Inability unwillingness swallow tablet . Unwilling consume standardize highfat breakfast ( approximately 800 1000 calorie ) consist approximately 33 g protein , 58 g carbohydrate , 75 g fat , respectively ( e.g . 2 egg fry butter , 2 strip bacon , 2 slice toast butter , 4 ounce hashbrown potato , 8 ounce whole milk ) . Subjects lactose intolerant A history malignancy type , surgically excise nonmelanomatous skin cancer situ cervical cancer within 5 year day dose . Donated great 500 mL blood blood product within 60 day dose . Receiving receive investigational drug ( use use investigational device ) within 30 day receive first dose study medication , least 5 elimination halflives ( whichever longer ) . Subjects previously expose AMG 853 . Use overthecounter prescription medication ( specifically include , limited , antacid , H2 blocker , proton pump inhibitor , aspirin nonsteroidal antiinflammatory drug [ NSAIDS ] ) within 30days dose . Acetaminophen ( 2 g per day ) analgesia hormone replacement therapy ( eg , estrogen ) allow . Use known inhibitor CYP3A4/Pgp ketoconazole , itraconazole , HIV protease inhibitor , nefazadone , cyclosporine , erythromycin , clindamycin , tetracycline , clarithromycin within 14 day 5 half life , ever longer ; grapefruit juice grapefruit containing product within 7 day prior investigational product administration . Use known CYP inducer rifampin , corticosteroid , anticonvulsant within 30 day 5 halflives , ever long , investigational product administration . Use herbal medicine ( eg , St. John 's wort ) within 30 day investigational product administration . All herbal medicine , vitamin , supplement consume subject within 30 day prior first dose investigational product continue use , appropriate , review Principal Investigator Amgen Medical Monitor . History hypersensitivity allergic reaction sulfonamide drug . Positive HIV antibody , hepatitis B surface antigen , hepatitis C antibody . Known history Gilbert 's syndrome . Any condition might reduce chance obtain data ( eg , know poor compliance ) require protocol might compromise ability give truly informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Amgen</keyword>
	<keyword>Healthy</keyword>
	<keyword>Adult</keyword>
</DOC>